ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Incorporating patient preference vital to study success
Jayne Galinsky, Senior Outcomes Researcher, shares the importance of learning and assessing patient preferences in clinical research.
Patient voice, empathy key to paediatric study design
Jacqui Whiteway, Senior Director of the Centre for Paediatric Clinical Development, discusses the unique challenges involved in designing a study when the patients involved are young children.
Tech advances making decentralised trial growth possible
Dr. Isaac R. Rodriguez-Chavez, Senior Vice President, Scientific and Clinical Affairs at ICON discusses the technology advancements that are making decentralised trial growth possible.
Decentralised clinical trial transformations are ‘here to stay’
Dr. Isaac R. Rodriguez-Chavez, Senior Vice President, Scientific and Clinical Affairs at ICON, discusses the various factors behind the DCT format's rapid rise and likely longevity in the drug development arena.
Improving early phase oncology clinical trial design: A case study
Tim Clark, VP Drug Development Solutions and Alan Phillips, Sr. Director Biostatistics present a case study on the first in human Bayesian Optimal Interval design.
ICON wins ‘Company of the Year’ at the Business & Finance Awards 2022
Steve Culter gives insight into ICON as a company along with his thoughts on winning this award.
What Biotech and Pharma need to consider about decentralised trials
Emily Mitchell, Executive Director, DCT Operations discusses the key considerations when implementing decentralised clinical trials, in addition to the success factors that lead to more patient-centric trials and increased patient recruitment, engagement and retention.
The surge of digital health technologies modernising clinical research
Dr. Isaac R. Rodriguez-Chavez outlines the key considerations when developing digital health technologies.
Cell and gene therapy specific market authorisation guidances
Brandon Fletcher, Principal, Cell and Gene Therapy, offers his insights on the key changes in regulatory guidance documents released by the US Food and Drug Agency.
Improving early phase oncology clinical trial design using Bayesian-based BOIN and BOP2 designs
Tim Clark, VP Drug Development Solutions, Martin Lachs, VP Project Management Oncology & Cell Therapeutics and Alan Phillips, Sr. Director Biostatistics, offer insights on selecting and implementing the appropriate model-based or model-assisted design for early phase oncology trials.